Just Diagnosed with Cirrhosis? What the First 30 Days Should Look Like
A new diagnosis of cirrhosis is not an emergency, but the first month decides a great deal. Four things must happen: find the cause, stage the liver, screen for varices, and start protecting what remains. For most compensated patients, a liver stiffness of 15 kPa or less with a platelet count of 150 or more means endoscopy can safely wait — the Baveno VII rule.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- Cirrhosis is a stage, not a sentence. Compensated cirrhosis with the cause removed can remain stable for decades; the first month is about making sure yours does.
- Every new diagnosis needs a cause. Hepatitis B and C serology, an honest alcohol history, metabolic screening, autoimmune and iron studies — and, in anyone under forty, a copper test for Wilson disease.
- Two scores stage the disease: Child-Pugh (A, B or C) and MELD. Two numbers — liver stiffness and platelet count — decide whether you need an endoscopy at all this year.
- Protein is not restricted. The EASL 2019 guideline asks for 1.2–1.5 g of protein per kilogram a day and a late-evening snack; the old low-protein advice is now considered harmful.
- Alcohol stops completely, whatever the cause. Painkillers of the NSAID class are off the list. Four vaccines go on it.
- An ultrasound every six months to look for liver cancer is non-negotiable, and the transplant conversation starts at the first sign of decompensation — not when it is too late.
A composite of a patient I meet most weeks. A 52-year-old schoolteacher from Dadar is told, after an ultrasound for vague tiredness, that her liver “looks cirrhotic”. She has never drunk alcohol. Her sugar has been borderline for years, her weight has crept up, and nobody has ever checked her for hepatitis B. She reaches my clinic having read enough online to be frightened and not enough to be useful.
Cirrhosis means the liver has scarred to the point where its architecture has changed. It does not mean the liver has failed. Many people live for decades with compensated cirrhosis — no fluid, no confusion, no bleeding — provided the cause is dealt with and the surveillance kept up. What separates them from the patients I meet in the ICU is usually what happened in the weeks after diagnosis.
This is the plan I would want a family to hold, week by week, anchored to Baveno VII, the EASL guidelines on decompensated cirrhosis and nutrition, and the AASLD liver cancer guidance. Educational, not a prescription — decisions for any one patient belong with the hepatologist who has the reports. If the word cirrhosis is itself still new, start there.
Week 1: confirm it, and find the cause
An ultrasound report saying “coarse echotexture, suggestive of cirrhosis” is a suspicion, not a diagnosis. The first job is to confirm it, and the tool for that is usually a FibroScan — transient elastography, a painless ten-minute scan that measures how stiff the liver is in kilopascals. Baveno VII puts the thresholds plainly: a stiffness under 10 kPa, with nothing else pointing to cirrhosis, rules out advanced disease; 10 to 15 kPa is suggestive; above 15 kPa is highly suggestive. A platelet count, albumin, bilirubin, INR and creatinine come from the same blood draw. Biopsy is now the exception, reserved for the cases where the cause is unclear or the numbers disagree — my post on FibroScan versus biopsy explains when each one earns its place.
Then the cause. This is the step most often skipped, and it is the one that changes the future most, because a cirrhotic liver with the insult removed behaves very differently from one still under attack. The standard panel: HBsAg and anti-HCV for the two viruses, a frank conversation about alcohol (quantity, pattern, years), fasting glucose, HbA1c, lipids and waist circumference for metabolic liver disease, autoimmune markers and immunoglobulins, iron studies, and — in anyone under forty — serum ceruloplasmin and urinary copper for Wilson disease, which is commoner in Indian practice than Western textbooks suggest. Alpha-1 antitrypsin completes the list. Two causes frequently coexist; a man who drinks and has diabetes has both working against him.
Write the questions down before the appointment. My list of questions to ask a liver specialist is a reasonable starting point. The one I most want to be asked is “what caused this, and can it be stopped?” — because for hepatitis C, hepatitis B and alcohol the honest answer is yes, and for metabolic disease it is increasingly yes as well.
Week 2: stage it — Child-Pugh, MELD, and the two numbers that decide endoscopy
Staging answers a different question from diagnosis: not “is it cirrhosis?” but “how much reserve is left, and how fast might it change?” Two scores do this. The Child-Pugh score, first described by Pugh and colleagues in 1973 for patients undergoing variceal surgery, combines bilirubin, albumin, INR, ascites and encephalopathy into a grade of A (5–6 points), B (7–9) or C (10–15). The MELD score, built by Kamath and the Mayo group in 2001 from bilirubin, creatinine and INR, predicts three-month mortality on a scale from 6 to 40 and is the currency of transplant waiting lists; its 2021 revision, MELD 3.0, adds sex and albumin and corrects a long-standing under-scoring of women. I have written a full explainer on MELD and Child-Pugh — keep your own numbers from each visit, because the trend tells you more than any single value.
Staging also includes portal hypertension — the raised pressure in the veins feeding the liver that causes varices, ascites and most of the drama of cirrhosis. Until recently that meant an endoscopy for everyone. Baveno VII, the 2021 international consensus, replaced that with two numbers you already have from week one. A liver stiffness of 15 kPa or less together with a platelet count of 150 × 10⁹/L or more rules out clinically significant portal hypertension, with a negative predictive value above 90%. A stiffness of 25 kPa or more rules it in. Between those lies a grey zone in which the hepatologist weighs the platelets, the cause and the body habitus.
What follows from that is simple. If portal hypertension is ruled out, no endoscopy is needed this year; the scan and the blood count are repeated annually, and endoscopy is triggered only if stiffness climbs to 20 kPa or platelets fall to 150. If portal hypertension is present, Baveno VII recommends a non-selective beta-blocker — carvedilol is the preferred agent in compensated cirrhosis — to prevent the first decompensation, and a patient on that treatment does not need a screening endoscopy either, because finding varices would not change the plan. Endoscopy is reserved for those who cannot take a beta-blocker and have a stiffness of 20 kPa or above or platelets at or below 150, and for anyone who already has ascites and is not on one. If you are sent for one, my guide to upper GI endoscopy covers what to expect, and the post on oesophageal varices explains what is done if they are found.
Week 3: protect the liver you have — alcohol, vaccines, and medicines to avoid
Alcohol stops. Completely, permanently, and regardless of whether alcohol caused the cirrhosis. A liver with no reserve cannot absorb the second insult, and every major guideline — the AASLD alcohol-associated liver disease guidance among them — treats abstinence as the single intervention that most changes survival. “Only on weekends” and “only beer” are not abstinence. If stopping is hard, say so; that is a medical problem with medical help, not a character flaw.
Vaccines go on the list the same week, because the ability to respond to them falls as the liver worsens — the time to vaccinate is early. The United States Advisory Committee on Immunization Practices recommends, for anyone with chronic liver disease, vaccination against hepatitis A and hepatitis B (after checking you are not already immune), a yearly influenza vaccine, pneumococcal vaccine, and the routine adult vaccines including tetanus-diphtheria-pertussis, zoster and SARS-CoV-2; inactivated vaccines are preferred, and live vaccines are avoided altogether after transplant. The evidence for influenza vaccination specifically is thin but points one way: a 2019 meta-analysis found vaccinated liver patients were 27% less likely to be admitted to hospital, and a chest infection is one of the commonest triggers for a stable cirrhotic to decompensate. Ask your hepatologist which of these you have had and which you need; the schedule is individual.
Then the medicine cabinet. The EASL 2018 guideline is unambiguous that non-steroidal anti-inflammatory drugs — ibuprofen, diclofenac, naproxen, aceclofenac and the rest — should not be used in patients with ascites, because they provoke sodium retention, low sodium and kidney injury; in practice most hepatologists extend that caution to all cirrhosis. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, common blood-pressure tablets, are generally avoided once ascites is present for the same reason, and aminoglycoside antibiotics are discouraged. Paracetamol in modest amounts is the safer painkiller, but every new prescription, every supplement and every ayurvedic or herbal preparation should be run past the liver team first — I have published on herbal liver injury in India and the cases are not rare. Bring every strip and bottle to the first consultation.
Week 4: eat for your muscles
The most damaging piece of folk advice in cirrhosis is “eat less protein”. It survives from a handful of uncontrolled studies in the 1950s, and the EASL 2019 nutrition guideline now calls protein restriction detrimental, permitted at most for a few days in severe encephalopathy or active bleeding. The cirrhotic liver cannot store glucose overnight the way a healthy one does, so after a few hours of fasting the body begins breaking down muscle for fuel. That is why cirrhotic patients lose muscle so fast, and why sarcopenia is one of the strongest predictors of a bad outcome.
The guideline targets are concrete: at least 35 kcal per kilogram of body weight a day in those who are not obese, 1.2 to 1.5 g of protein per kilogram a day, small frequent meals, a breakfast containing protein, and a late-evening snack so that the overnight fast is as short as possible. The late snack is not a comfort measure. In a 12-month randomised trial from Auckland, 103 patients given their supplement at night rather than in the day gained roughly two kilograms of lean tissue; those fed the same supplement in daytime gained none. Salt, if there is ascites, is moderately restricted — the EASL figure is 80–120 mmol of sodium a day, roughly 4.6–6.9 g of salt, which in practice means no added salt and no packaged food, not a tasteless diet that makes you eat less.
I should be precise about what nutrition can and cannot do, because I ran one of the few randomised trials on the question. At ILBS we randomised 104 malnourished men with alcohol-related cirrhosis to standard dietary advice or to an aggressive regimen of higher calories and protein with a polymeric supplement for three months. The intervention arm did better on nutritional status — Royal Free Hospital global assessment improved in 33% against 14% — and had better resolution of ascites, 53% against 44%. Twelve-month survival, however, was the same in both arms. What did predict survival, irrespective of which arm a patient was in, was actually eating: those who achieved more than 25 kcal and 0.8 g of protein per kilogram a day lived longer. The lesson is not that nutrition fails. It is that a prescription on paper does nothing; intake does. Our nutrition in cirrhosis guide translates these targets into Indian meals.
The surveillance calendar, and the red flags
Every patient with cirrhosis, from any cause, is at risk of hepatocellular carcinoma, and the AASLD 2023 guidance is clear that surveillance belongs to all of them who would be candidates for curative treatment if a cancer were found. Six months is the interval — semiannual surveillance catches tumours at an earlier stage and improves survival compared with annual checks, and more frequent scanning did not help. An ultrasound by someone who scans livers routinely, usually paired with an AFP blood test, is the test. A six-monthly scan does not feel urgent when you are well. That is exactly why it gets missed, and why a small curable tumour becomes a large incurable one between a scan in January and the next one in two years’ time. Put the dates in the phone now. My post on liver cancer surveillance in India explains what happens if something is seen.
Liver stiffness and the blood panel are repeated roughly every twelve months in compensated disease, as Baveno VII suggests; a fall in stiffness of 20% or more to below 20 kPa, after the cause is removed, is a genuinely good sign. The question I am asked most — can the damage reverse? — has a more hopeful answer than it did a decade ago, and this is the number that tells you whether it is happening.
Finally, the red flags — the things that mean “same day”, not “next appointment”. Vomiting blood or passing black, tarry stools. New confusion, unusual sleepiness, or a family member saying you are “not yourself”. Fever with abdominal pain, or a belly that swells over days rather than months. Deepening yellowness of the eyes. A sharp fall in urine output. Any of these in a person with cirrhosis is a potential decompensation — ascites, encephalopathy, variceal bleeding or infection — and the outcome depends heavily on how quickly it is treated.
When transplant enters the conversation
Not now, for most newly diagnosed patients. Compensated Child-Pugh A cirrhosis with the cause controlled is managed, not transplanted. But the conversation should be had early enough that it is a plan and not a panic, and the triggers are well defined. The EASL 2018 guideline asks that a patient whose ascites has become refractory to diuretics be referred to a transplant centre immediately, that anyone who recovers from spontaneous bacterial peritonitis be considered for transplant, and that acute-on-chronic liver failure prompt early referral because the window closes fast. Baveno VII says it in one line: patients with decompensated cirrhosis should be considered for liver transplantation. In practice, the first episode of decompensation — fluid, confusion or a bleed — or a MELD score climbing into the mid-teens is when evaluation begins.
Evaluation is not the same as surgery; many patients are assessed, listed and then stabilised for years. But a living-donor transplant takes months to organise — donor work-up, finances, fitness — and families who start that process at the first decompensation have options that families who start it in the ICU do not. My transplant preparation checklist lays out the steps. Across more than 1,000 transplants our teams have been involved in, roughly 300 of them complex, with survival of about 92%, the single factor I would most like to change is the timing of referral.
The table below is the first month on one page. Print it.
| When | What | Why it matters | Guideline anchor |
|---|---|---|---|
| Week 1 | FibroScan (liver stiffness); platelets, albumin, bilirubin, INR, creatinine, sodium; abdominal ultrasound with Doppler | Confirms cirrhosis (stiffness >15 kPa highly suggestive) and gives the raw data for staging | Baveno VII 2.4 |
| Week 1 | Cause work-up: HBsAg, anti-HCV, alcohol history, HbA1c and lipids, autoimmune markers, iron studies, ceruloplasmin/urinary copper if under 40, alpha-1 antitrypsin | A cause that can be removed changes the whole trajectory | Standard aetiology panel |
| Week 2 | Child-Pugh grade and MELD score calculated and recorded | Baseline reserve; the trend over visits matters more than one value | Pugh 1973; Kamath 2001; MELD 3.0 2021 |
| Week 2 | Apply the stiffness/platelet rule; endoscopy or beta-blocker decision | LSM ≤15 kPa + platelets ≥150 → no endoscopy, repeat yearly; LSM ≥25 kPa → portal hypertension, beta-blocker discussion; cannot take beta-blocker and LSM ≥20 or platelets ≤150 → endoscopy | Baveno VII 2.15, 2.16, 2.19, 5.15, 5.17 |
| Week 3 | Alcohol: complete abstinence, with support if needed | The intervention with the largest effect on survival in any cirrhosis | AASLD ALD guidance 2019 |
| Week 3 | Vaccines: hepatitis A and B (if not immune), influenza yearly, pneumococcal, routine adult vaccines | Response falls as the liver worsens — vaccinate early; infection is a common trigger of decompensation | ACIP, via Alukal 2022 |
| Week 3 | Medicine review: stop NSAIDs; flag ACE inhibitors/ARBs and aminoglycosides; declare every herbal and supplement | NSAIDs cause sodium retention, low sodium and kidney injury in ascites | EASL 2018 (II-2;1) |
| Week 4 | Dietitian visit: ≥35 kcal/kg and 1.2–1.5 g protein/kg daily, late-evening snack, protein at breakfast, no fasting; salt 80–120 mmol/day only if ascites | Prevents muscle loss; protein restriction is harmful | EASL nutrition 2019; EASL 2018 |
| Week 4 | Book the six-monthly HCC ultrasound ± AFP and the annual FibroScan; save the red-flag list | Semiannual surveillance finds cancer at a curable stage | AASLD HCC 2023; Baveno VII 2.12 |
| Day 30 | Review: cause confirmed? stage recorded? endoscopy decided? vaccines started? diet plan in hand? surveillance dates fixed? transplant discussed if decompensated? | Seven yes answers mean the first month did its job | — |
Frequently asked questions
Is cirrhosis always fatal?
No. Compensated cirrhosis — no fluid, no confusion, no bleeding — can remain stable for decades once the cause is removed and surveillance is kept up. The danger is decompensation, and most of the first month is about reducing the chance of it: treating the cause, screening for varices, protecting the kidneys and muscles, and watching for liver cancer.
Do I need an endoscopy if I have just been diagnosed with cirrhosis?
Not always. Under the Baveno VII consensus, a liver stiffness of 15 kPa or less with a platelet count of 150 or more rules out clinically significant portal hypertension, and endoscopy can be deferred with yearly repeat testing. Patients on a non-selective beta-blocker for portal hypertension also do not need screening endoscopy. It remains necessary for those who cannot take a beta-blocker and have a stiffness of 20 kPa or more or platelets of 150 or below, and for anyone with ascites who is not on one.
Should I eat less protein if I have cirrhosis?
No. The EASL 2019 nutrition guideline recommends 1.2–1.5 g of protein per kilogram of body weight a day, at least 35 kcal per kilogram in non-obese patients, small frequent meals and a late-evening snack. Protein restriction is now considered harmful, allowed only for a few days in severe encephalopathy or active bleeding. Muscle loss is one of the strongest predictors of poor outcome in cirrhosis.
Which painkillers are safe in cirrhosis?
Non-steroidal anti-inflammatory drugs such as ibuprofen, diclofenac and naproxen should be avoided — the EASL 2018 guideline states they must not be used in patients with ascites because of sodium retention, low sodium and kidney injury. Paracetamol in modest amounts is generally the safer choice, but the dose and every other medicine, supplement or herbal product should be confirmed with your hepatologist.
How often do I need a scan for liver cancer?
Every six months, by ultrasound, usually with an AFP blood test, for anyone with cirrhosis who would be a candidate for curative treatment. The AASLD 2023 guidance notes that six-monthly surveillance detects tumours at an earlier stage and improves survival compared with annual scanning.
When should I start thinking about a liver transplant?
At the first episode of decompensation — ascites, encephalopathy or variceal bleeding — or when the MELD score rises steadily. The EASL 2018 guideline asks for immediate transplant-centre referral once ascites becomes refractory to diuretics, consideration after recovery from spontaneous bacterial peritonitis, and early referral in acute-on-chronic liver failure. Evaluation is not surgery; starting early keeps options open.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. PMID 35120736. doi:10.1016/j.jhep.2021.12.022
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. PMID 29653741. doi:10.1016/j.jhep.2018.03.024
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–193. PMID 30144956. doi:10.1016/j.jhep.2018.06.024
- Kalal C, Benjamin J, Shasthry V, Kumar G, Sharma MK, Joshi YK, Sarin SK. Effect of long-term aggressive nutrition therapy on survival in patients with alcohol-related cirrhosis: a randomized controlled trial. Indian J Gastroenterol. 2022;41(1):52–62. PMID 35235198. doi:10.1007/s12664-021-01187-3
- Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557–566. PMID 18627001. doi:10.1002/hep.22367
- Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. PMID 37199193. doi:10.1097/HEP.0000000000000466
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470. PMID 11172350. doi:10.1053/jhep.2001.22172
- Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the Model for End-Stage Liver Disease updated for the modern era. Gastroenterology. 2021;161(6):1887–1895.e4. PMID 34481845. doi:10.1053/j.gastro.2021.08.050
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649. PMID 4541913. doi:10.1002/bjs.1800600817
- Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–333. PMID 31314133. doi:10.1002/hep.30866
- Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in chronic liver disease: an update. J Clin Exp Hepatol. 2022;12(3):937–947. PMID 34975241. doi:10.1016/j.jceh.2021.12.003
- Härmälä S, Parisinos CA, Shallcross L, O’Brien A, Hayward A. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ Open. 2019;9(9):e031070. PMID 31494620. doi:10.1136/bmjopen-2019-031070
